Information about Flucytosine
Flucytosine is an antifungal agent used to treat severe infections caused by candida and cryptococcus.
Liver safety of Flucytosine
Flucytosine therapy can cause transient mild-to-moderate serum aminotransferase elevations and has been mentioned as a very rare cause of clinically apparent acute drug induced liver injury.
Mechanism of action of Flucytosine
Flucytosine (floo sye' toe zeen) is a fluorinated pyrimidine analogue which has potent fungicidal activity. Flucytosine is taken up by fungal cells and converted to fluorouracil, which blocks pyrimidine metabolism and may be converted to metabolites that block DNA synthesis. Human cells do not possess the enzymes to convert flucytosine to these toxic metabolites. Flucytosine is active against several Candidal and Cryptococcal species.
FDA approval information for Flucytosine
Flucytosine was approved for use in the United States in 1971, but has been largely replaced by better tolerated and more potent antifungal agents such as amphotericin and the azoles.
Dosage and administration for Flucytosine
Flucytosine is available as tablets of 250 and 500 mg in generic forms and under the brand name of Ancobon. The usual recommended dose is 50 to 150 mg/kg daily in divided doses (usually every six hours) and it is usually used in combination with other antifungal agents, most often amphotericin B.
Side effects of Flucytosine
The following drugs are antifungal agents:
- Amphotericin B